| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 8.20 | 0.23 | 0.50 | 1.89 |
| Receivables | — | — | — | — |
| Inventory | 1.73 | — | — | — |
| Other | 21.66 | 10.82 | 9.55 | 9.60 |
| 31.01 | 11.34 | 10.32 | 11.70 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 12.11 | 0.89 | 0.34 | 0.52 |
| ST’ Debt | 0.52 | 1.26 | — | — |
| Other | 0.36 | 14.05 | 8.41 | 2.23 |
| 14.77 | 16.20 | 8.75 | 2.75 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.48 | 0.18 | 0.05 | — |
—
|
| ’23 | 0.40 | 0.79 | 0.73 | 0.55 |
2.47
|
| ’22 | 0.96 | 1.07 | 0.65 | 0.45 |
3.14
|
| ’21 | 0.07 | 0.23 | 0.46 | 0.42 |
1.17
|
| ’20 | 0.01 | 0.00 | 0.07 | 0.05 |
0.13
|
| ’19 | 0.10 | 0.04 | — | 0.05 |
0.19
|
| ’18 | 0.02 | 0.05 | 0.01 | 0.01 |
0.08
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.02) | (1.33) | — | — |
—
|
| ’25 | (2.36) | (1.55) | (1.65) | (3.18) |
(8.74)
|
| ’24 | (4.42) | (4.33) | (4.01) | (1.11) |
(13.86)
|
| ’23 | (6.14) | (6.10) | (6.22) | (5.77) |
(24.24)
|
| ’22 | (5.33) | (5.93) | (6.70) | (3.05) |
(21.01)
|
| ’21 | (4.52) | (5.94) | (4.65) | (5.36) |
(20.47)
|
| ’20 | (2.93) | (4.04) | (3.61) | (3.70) |
(14.29)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.02) | (1.33) | — | — |
—
|
| ’25 | 1.36 | (0.64) | 0.82 | (3.15) |
(1.61)
|
| ’24 | (5.54) | (5.05) | 4.68 | (0.39) |
(6.30)
|
| ’23 | (29.07) | (29.76) | (25.89) | (8.41) |
(93.13)
|
| ’22 | (11.09) | (30.64) | (21.11) | (25.65) |
(88.48)
|
| ’21 | (5.73) | (7.17) | (6.38) | (6.91) |
(26.19)
|
| ’20 | (3.53) | (4.94) | (4.66) | (5.04) |
(18.16)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.26) | (0.32) | — | — |
—
|
| ’25 | 0.10 | (0.87) | (0.36) | — |
(4.77)
|
| ’24 | (2.90) | (13.08) | (0.88) | — |
(38.65)
|
| ’23 | (1.80) | (1.80) | (1.60) | (2.19) |
(7.17)
|
| ’22 | (1.40) | (1.60) | (1.60) | (1.80) |
(6.20)
|
| ’21 | (1.20) | (1.40) | (2.00) | (1.60) |
(6.40)
|
| ’20 | (2.20) | (2.20) | (1.80) | (2.80) |
(9.00)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 11.64 | 1.57 | 0.47 | 0.50 | — | — | — |
Low Price
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 47.40 | 23.60 | 2.95 | 2.95 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 100 | 82 | 4 | 3 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.03 | 0.03 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.14 | 2.47 | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (334.52%) | (518.02%) | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (22.16) | (13.84) | (11.38) | (2.23) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (706.32%) | (559.75%) | 0.00% | 0.00% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (22.16) | (27.56) | (149.19) | (18.49) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.02 | 2.16 | 0.90 | — | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.82 | 0.64 | 0.00 | 0.00 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | (6.20) | (7.17) | (38.65) | (4.77) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.48) | (6.30) | (3.59) | (2.26) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (17.60) | (17.92) | 1.96 | 1.84 | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (23.08) | (24.22) | (1.63) | (0.42) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 50.07 | 42.93 | 4.10 | (0.49) | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.83 | 3.84 | 3.86 | 3.87 | — | — | — |
Shares
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | — | — | — | — | — |
PE Ratio
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.48 | 4.34 | — | — | — | — | — |
PS Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.32 | 0.07 | — | — | — | — | — |
PB Ratio
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.16) | 3.05 | — | — | — | — | — |
EV/Sales
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.36 | (0.08) | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (21.01) | (24.24) | (13.86) | (8.74) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (67.48) | (68.89) | 7.56 | 7.13 | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (88.48) | (93.13) | (6.30) | (1.61) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 90.62 | 16.24 | (4.86) | 1.57 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.67 | 5.02 | 3.26 | 3.49 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (92.97) | (3.18) | 3.03 | 2.98 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 191.92 | 165.02 | 15.84 | (1.89) | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.02%) | (13.73%) | (134.64%) | (83.28%) | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.10%) | (5.28%) | (31.89%) | (229.59%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.92%) | (15.44%) | (164.98%) | (265.10%) | — | — | — |
ROE
|
AquaBounty Technologies (AQB), pioneers of the FDA-approved AquAdvantage GM salmon, promised to revolutionize aquaculture but has delivered a biotech horror story of hype, hype crashes, and hemorrhaging cash. Revenue rocketed 820% to $11.75 million in 2021 on commercial breakthroughs, only to crater 21% in 2023 and vanish entirely in 2024 amid a 95% employee purge—from 82 to just 4—signaling a desperate pivot or shutdown. Gross margins stay mired in negative territory, cumulative losses explode to $149 million, and relentless share dilution has gutted book value per share by 84%, echoing the gene therapy busts of the early 2000s where ambition outran execution.
Cash burn remains ferocious, with capex black holes like 2022’s $67.5 million spike yielding abysmal ROIC and ROE, while stock prices have plunged 98% from peaks, trading at rock-bottom multiples that scream skepticism over the “sustainable protein” narrative. Insider silence—no buys amid the lows—offers no comfort, and international barriers plus consumer aversion to Frankenfish continue throttling adoption.
Yet, 2025 forecasts whisper stabilization: $1.3 million revenue, slashed losses, and BVPS rebound. Is this a turnaround trap or undervalued gem in a funding winter? Fundamentals howl caution—value destruction over innovation—but biotech survivors thrive on pivots; dive deeper to weigh if AQB merits a speculative watchlist slot or swift avoidance.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.